Item 5. Other Information
Item 5. OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the quarter ended March 31, 2025, no director or executive officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Pacira BioSciences, Inc. | Q1 2025 Form 10-Q | Page 52
Table of Contents
Item 6. EXHIBITS
The exhibits listed below are filed or furnished as part of this report.
Exhibit Number Description
3.1
Third Amended and Restated Bylaws. (1)
10.1
Settlement Agreement, dated April 7, 2025, by and between Pacira BioSciences, Inc. and Pacira Pharmaceuticals, Inc. with Fresenius Kabi USA, LLC, eVenus Pharmaceutical Laboratories Inc., and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (f/k/a Jiangsu Hengrui Medicine Co., Ltd.).* †† ##
10.2
Amended and Restated 2014 Inducement Plan. *** (2)
10.3
Form of Nonstatutory Stock Option Agreement under the Amended and Restated 2014 Inducement Plan. *** (3)
10.4
Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2014 Inducement Plan. *** (4)
31.1
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
31.2
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.*
32.1
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101 The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended March 31, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive Income; (iv) the Condensed Consolidated Statements of Stockholders’ Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.*
104 Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101).
* Filed herewith.
** Furnished herewith.
*** Denotes management contract or compensatory plan or arrangement.
††
Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information (i) is not material and (ii) is the type that the Registrant treats as private or confidential.
## Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to supplementally furnish copies of any omitted schedules and exhibits to the Securities and Exchange Commission upon request.
(1) Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K, filed on March 14, 2025.
(2) Incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K, filed on January 21, 2025.
(3) Incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K, filed on January 21, 2025.
(4) Incorporated by reference to Exhibit 10.3 to the registrant’s Current Report on Form 8-K, filed on January 21, 2025.
Pacira BioSciences, Inc. | Q1 2025 Form 10-Q | Page 53
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PACIRA BIOSCIENCES, INC.
(REGISTRANT)
Date: May 8, 2025 By: /s/ FRANK D. LEE
Frank D. Lee
Chief Executive Officer and Director
(Principal Executive Officer)
Date: May 8, 2025 By: /s/ SHAWN M. CROSS
Shawn M. Cross
Chief Financial Officer
(Principal Financial Officer)
Pacira BioSciences, Inc. | Q1 2025 Form 10-Q | Page 54
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.